PMID- 36340629
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231202
IS  - 0018-5787 (Print)
IS  - 1945-1253 (Electronic)
IS  - 0018-5787 (Linking)
VI  - 57
IP  - 6
DP  - 2022 Dec
TI  - Safety and Efficacy Analysis of Apixaban Compared to Heparins in Hospitalized 
      Non-Critically Ill COVID-19 Patients.
PG  - 727-733
LID - 10.1177/00185787221095764 [doi]
AB  - Purpose: Heparin-based regimens are recommended for anticoagulation in 
      hospitalized patients with COVID-19 though a study reported similar mortality 
      with apixaban in critically ill hospitalized COVID-19 patients. Our pilot study 
      sought to determine the differences in all-cause mortality, venous 
      thromboembolism (VTE), and bleeding events between apixaban and therapeutic 
      heparin-based regimens in hospitalized non-critically ill COVID-19 patients. 
      Methods: We conducted a retrospective analysis of non-critically ill COVID-19 
      patients aged >/= 18 years admitted to 3 campuses of Montefiore Medical Center 
      during the first (March 2020 to May 2020) and second (January 2021 to February 
      2021) COVID-19 surges, who received within 48 hours of admission and continued 
      for >/=72 hours a therapeutic dose of low-molecular-weight heparin (LMWH), 
      unfractionated heparin (UFH), or any apixaban dose for VTE prophylaxis. Outcomes 
      data analyzed included mortality, suspected or imaging-confirmed VTE, and 
      bleeding using a defined criteria. Results: Overall, 162 patients met eligibility 
      for analysis. Baseline characteristics were similar between the 2 groups except 
      liver and renal functions. Mortality occurred in 10 (13.3%) patients on apixaban 
      and 23 (26.4%) patients on a heparin-based regimen (P = .059). Confirmed VTE 
      events were not different between the groups (8% vs 13.8%, P = .359), but higher 
      incidence of bleeding occurred in heparin-based group (4% vs 52.9%, P < .001). 
      Conclusion: There were no differences in mortality or confirmed VTE between 
      apixaban and heparin-based regimens except for more bleeding events with the 
      heparins. This study highlights the utility of apixaban in COVID-19.
CI  - (c) The Author(s) 2022.
FAU - Appiah, Daniel
AU  - Appiah D
AD  - Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
FAU - Quinn, Nicholas J
AU  - Quinn NJ
AUID- ORCID: 0000-0002-9703-5845
AD  - Montefiore Medical Center, Bronx, NY, USA.
FAU - Messing, Emily G
AU  - Messing EG
AD  - Montefiore Medical Center, Bronx, NY, USA.
FAU - Veltri, Keith T
AU  - Veltri KT
AD  - Montefiore Medical Center, Bronx, NY, USA.
AD  - Touro College of Pharmacy, New York, NY, USA.
LA  - eng
PT  - Journal Article
DEP - 20220519
PL  - United States
TA  - Hosp Pharm
JT  - Hospital pharmacy
JID - 0043175
PMC - PMC9631005
OTO - NOTNLM
OT  - COVID
OT  - anticoagulants
OT  - disease management
OT  - respiratory
COIS- The author(s) declared no potential conflicts of interest with respect to the 
      research, authorship, and/or publication of this article.
EDAT- 2022/11/08 06:00
MHDA- 2022/11/08 06:01
PMCR- 2023/12/01
CRDT- 2022/11/07 05:03
PHST- 2022/11/07 05:03 [entrez]
PHST- 2022/11/08 06:00 [pubmed]
PHST- 2022/11/08 06:01 [medline]
PHST- 2023/12/01 00:00 [pmc-release]
AID - 10.1177_00185787221095764 [pii]
AID - 10.1177/00185787221095764 [doi]
PST - ppublish
SO  - Hosp Pharm. 2022 Dec;57(6):727-733. doi: 10.1177/00185787221095764. Epub 2022 May 
      19.